Canada markets open in 4 hours 44 minutes

Curis, Inc. (CRIS)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
8.50-0.30 (-3.41%)
At close: 04:00PM EDT

Curis, Inc.

Building C
Suite 500 128 Spring Street
Lexington, MA 02421
United States
617 503 6500
https://www.curis.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees49

Key Executives

NameTitlePayExercisedYear Born
Mr. James E. DentzerPresident, CEO, Secretary, Treasurer & Director1.07MN/A1967
Ms. Diantha Duvall CPA, M.B.A.CFO and Principal Financial & Accounting Officer719.02kN/A1972
Dr. Jonathan B. Zung Ph.D.Chief Development Officer691.27kN/A1965
Mr. Mark W. NoelVice President of Technology Management & Intellectual Property279.28k85.7k1959
Dr. Robert E. Martell M.D., Ph.D.Chief Scientific Officer537.15kN/A1963
Ms. Elif McDonaldVP of Investor Relations & Corporate CommunicationsN/AN/AN/A
Dr. Reinhard Wilhelm von Roemeling M.D.Senior Vice President of Clinical DevelopmentN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Curis, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.